Plain-English translation of NCT03973671 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Urinary Bladder Neoplasms research guide →This is a registry study — meaning researchers are collecting detailed medical information from patients diagnosed with non-muscle-invasive bladder cancer. No experimental medication or treatment is being tested. Instead, doctors will treat you according to current standard guidelines while carefully documenting your medical history, surgery details, and how you recover over time.
Doctors want to better understand which patients are at higher risk for their bladder cancer returning or worsening after treatment. By collecting information from many patients treated the same way, researchers hope to develop a tool that will help predict outcomes and improve how follow-up care is planned for future patients.
You likely qualify if…
You likely don't qualify if…
You will receive your standard bladder cancer treatment — such as surgery or biopsy — according to normal medical care. The main difference is that your doctors will record detailed information about your case, surgery, and recovery in a secure computer system. Over time, you'll be followed up through regular clinic visits as you normally would be, and your follow-up information will also be collected. All your information will be kept anonymous.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Belgium
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
KU Leuven
Enrollment target
~300 participants
Started
May 2020
Primary completion
May 2027
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Murat Akand, MD
Assistant Professor
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.